CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, February 29, 2024 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential…

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 28, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential…

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development

Partners able to claim up to 30% tax relief

Collaboration to accelerate research to determine role of GBA gene

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced…

CAMBRIDGE, Mass. And ROSTOCK, Germany and BERLIN, December 19, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), today announced the voting…

Centogene N.V. (Nasdaq: CNTG) today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT…

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to…

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads